RenovaCare Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound Healing
RenovaCare has made progress on its CELLMIST 1 clinical trial, focusing on the safety and feasibility of the SkinGun™ and CellMist™ System for treating burn wounds. The trial is currently screening patients at its first burn center, with plans to expand to four centers in the U.S. The study aims to enroll 14 subjects aged 18-65 with partial-thickness burn wounds. Each subject will receive treatment within seven days of injury, followed by seven follow-up visits over 12 months to evaluate safety and recovery.
- CELLMIST 1 clinical trial initiated and screening patients.
- Plans to expand clinical trials to four centers in the U.S.
- One potential clinical site withdrew from consideration.
- Another site deferred negotiations for expansion.
ROSELAND, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for the regeneration of skin and other organs and tissues, today provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient.
Currently, CELLMIST 1, the clinical trial is activated and screening patients at its first burn center.
The Company plans to expand its clinical trial to up to four centers in the United States. One site is currently under active negotiation; another candidate site has voluntarily withdrawn from consideration; a fourth clinical site has decided to defer continued negotiations to a later date.
The CELLMIST 1 clinical study plans to enroll 14 human subjects between 18 and 65 years old that have partial-thickness, second-degree thermal burn wounds encompassing <
Seven follow-up visits over 12 months will evaluate the safety and recovery of each subject.
Further details of the CELLMIST 1 clinical study with the RenovaCare Electronic SkinGun™ spray device and CellMist™ System can be found at www.clinicaltrials.gov.
About RenovaCare
RenovaCare, Inc. is developing new-generation autologous (self-donated) cell therapies for the regeneration of human tissues. The Company’s initial product under development targets the body’s largest organ, the skin. The Company’s flagship technology, the CellMist™ System, harvests a patient’s own stem cells from a small area of skin, generally around 1 square inch, and suspends them in the water based CellMist™ Solution. The suspension is then delicately sprayed onto the wound using the SkinGun™ deposition device, where it begins to grow new skin at the cellular level.
RenovaCare is currently developing its CellMist™ System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars.
RenovaCare products are currently in development. They are not available for sale in the United States. There is no assurance that the Company’s planned or filed submissions to the U.S. Food and Drug Administration will be accepted or cleared by the FDA.
For additional information, please call Amit Singh at: 1-888-398-0202 or visit: https://renovacareinc.com
To receive future press releases via email, please visit:
https://renovacareinc.com/investors/register/
Follow us on LinkedIn: https://www.linkedin.com/company/renovacare-inc-/
Follow us on Twitter: https://twitter.com/RenovaCareInc
Follow us on Facebook: https://www.facebook.com/renovacarercar
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using Securities and Exchange Commission (SEC) filings and press releases. We use our website and social media to communicate with our subscribers, shareholders and the public about the Company, RenovaCare, Inc., development and other corporate matters that are in the public domain. At this time, the Company will not post information on social media that could be deemed to be material information unless that information was provided to public distribution channels first.
We encourage investors, the media, and others interested in the Company to review the information we post on the Company’s website and the social media channels listed below:
- Twitter
* This list may be updated from time to time.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although RenovaCare, Inc. (the “Company”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: the timing and success of clinical and preclinical studies of product candidates, the potential timing and success of the Company’s product programs through their individual product development and regulatory approval processes, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, obsolescence of the Company’s technologies, technical problems with the Company’s research, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that the Company will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8eabf386-45a3-4af0-8deb-3e7b6329a405
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
FAQ
What is the CELLMIST 1 clinical trial about?
How many patients will be enrolled in the CELLMIST 1 trial?
What are the next steps for RenovaCare's clinical trials?
How will the effectiveness of the treatment be evaluated?
What is the significance of the SkinGun™ and CellMist™ System?
